PMV Pharmaceuticals, Inc

PMV Pharmaceuticals, Inc

Compare this stock

PMVP Stock Report Card

$

VolatilityTechnicalsSentimentProfitPerformanceEarnings

33%

Performance

Score:

10/100

PMVP returned -82.93% in the last 12 months. Based on SPY's performance of 9.73%, its performance is below average giving it a score of 10 of 100.

Sentiment

Score:

68/100

PMVP had a bullish sentiment score of 68.36% across Twitter and StockTwits over the last 12 months. It had an average of 10.94 posts, 3.32 comments, and 11.68 likes per day.

Technicals

Score:

43/100

PMVP receives a 42 of 100 based on 14 indicators. 5 are bullish, 7 are bearish.

Earnings

Score:

49/100

PMVP has missed earnings 3 times in the last 20 quarters.

Profit

Score:

10/100

Out of the last 17 quarters, PMVP has had 0 profitable quarters and has increased their profits year over year on 0 of them.

Volatility

Score:

33/100

PMVP has had a lower than average amount of volatility over the last 12 months giving it a score of 33 of 100.

PMV Pharmaceuticals, Inc Summary

Nasdaq / PMVP
Healthcare
Biotechnology
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.